Antisense Oligonucleotide Exon Skipping for DMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Duchenne muscular dystrophy (DMD) are inadequate in effectively restoring dystrophin expression and muscle function, as they often result in severe side effects and limited efficacy, particularly in males who suffer from premature muscle degeneration and respiratory or heart failure.
Innovation Solution
The method involves using antisense oligonucleotides (AONs) to induce skipping of specific exons in the DMD pre-mRNA, specifically exons 43, 46, 50-53, to restore the open reading frame and promote the production of functional dystrophin protein, thereby alleviating muscle symptoms and improving muscle function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides are used to induce exon skipping, then dystrophin expression is restored, but severe side effects occur
Solution Approach 1:
The patent modifies the chemical parameters of oligonucleotides by using 2'-O-methyl RNA modifications and phosphorothioate backbones, which change the physical and chemical properties to reduce immunogenicity and nuclease degradation while maintaining exon skipping efficacy
Solution Approach 2:
The invention creates composite oligonucleotide structures combining modified sugar moieties (2'-O-methyl RNA) with modified backbone linkages (phosphorothioate), resulting in a molecule that integrates both therapeutic function and reduced side effects
2Reliability
If current therapies are applied to restore dystrophin expression, then muscle function improves, but durability of treatment outcomes is limited
Solution Approach 1:
The patent employs multiple oligonucleotide sequences targeting different regions of the DMD gene, using partial redundancy to ensure sustained dystrophin restoration even if individual sequences have variable efficacy or are degraded over time
3Productivity
If exon skipping is induced in DMD pre-mRNA, then functional dystrophin production increases, but aberrant dystrophin production persists
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to specific sequences in the DMD pre-mRNA, acting as mediators to redirect splicing machinery and promote exon skipping while minimizing aberrant splicing events through optimized sequence design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to significant dystrophin expression in muscle fibers, improving muscle function and reducing aberrant dystrophin production, thereby prolonging ambulation and overall quality of life for DMD patients, with minimal side effects.
Implementation Method 1
antisense oligonucleotides (AONs) interfering with splicing signals the skipping of specific exons can be induced in the DMD pre-mRNA
Implementation Method 2
specific modification of splicing in order to restore the disrupted reading frame of the dystrophin transcript
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates a method wherein a molecule is used for inducing and/or promoting skipping of at least one of exon 43, exon 46, exons 50-53 of the DMD pre-mRNA in a patient, preferably in an isolated cell of a patient, the method comprising providing said cell and/or said patient with a molecule. The invention also relates to said molecule as such.